Corona Remedies

Corona Remedies Reports 21.9% Q1 Revenue Growth as EBITDA Margins Hit 22%

Corona Remedies Ltd (CORONA) reported ₹422.43 Cr revenue for Q1 FY27, up 21.9% YoY. Management highlights 30.1% PAT growth and new hormonal facility commissioning.

Corona Remedies · 10 Aug 2026, 5:56 PM IST